Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice

Biochemical and Biophysical Research Communications

Volumn 345, Issue 1, 2006, Pages 85-92

  Kaneko, Takashi ^a   Murakami, Takashi ^a   Kawana, Harumi ^a   Takahashi, Masafumi ^a   Yasue, Tokutaro ^b   Kobayashi, Eiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

FTY720; Hepatitis; KRP203; Lymphocyte homing

Indexed keywords

2 AMINO 2 [3 [4 (3 BENZYLOXYPHENYLSULFANYL) 2 CHLOROPHENYL]ETHYL]PROPAN 1,3 DIOL; AMINOTRANSFERASE; CHEMOKINE RECEPTOR CCR4; CONCANAVALIN A; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; KRP 203; SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; HEPATITIS; LIVER; LIVER INJURY; LYMPH NODE; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; CONCANAVALIN A; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATITIS, TOXIC; LIVER; LYMPHOCYTES; MALE; MICE; MICE, INBRED BALB C; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME;

ANIMALIA;

EID: 33646437280     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.04.067     Document Type: Article

References (29)

1. Heneghan M.A., and McFarlane I.G. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35 (2002) 7-13
2. Kita H., Mackay I.R., Van De Water J., and Gershwin M.E. The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 120 (2001) 1485-1501
3. Bogdanos D.P., Mieli-Vergani G., and Vergani D. Virus, liver and autoimmunity. Dig. Liver Dis. 32 (2000) 440-446
4. Rehermann B., and Chisari F.V. Cell mediated immune response to the hepatitis C virus. Curr. Top. Microbiol. Immunol. 242 (2000) 299-325
5. Batey R.G., Cao Q., and Gould B. Lymphocyte-mediated liver injury in alcohol-related hepatitis. Alcohol 27 (2002) 37-41
6. Lohr H.F., Schlaak J.F., Lohse A.W., Bocher W.O., Arenz M., Gerken G., and Meyer Zum Buschenfelde K.H. Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis. Hepatology 24 (1996) 1416-1421
7. Napoli J., Bishop G.A., McGuinness P.H., Painter D.M., and McCaughan G.W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24 (1996) 759-765
8. Rosen H.R., Miner C., Sasaki A.W., Lewinsohn D.M., Conrad A.J., Bakke A., Bouwer H.G., and Hinrichs D.J. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 35 (2002) 190-198
9. Chang K.M., Thimme R., Melpolder J.J., Oldach D., Pemberton J., Moorhead-Loudis J., McHutchison J.G., Alter H.J., and Chisari F.V. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 33 (2001) 267-276
10. Chisari F.V. Cytotoxic T cells and viral hepatitis. J. Clin. Invest. 99 (1997) 1472-1477
11. Tiegs G., Hentschel J., and Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 90 (1992) 196-203
12. Yanagawa Y., Sugahara K., Kataoka H., Kawaguchi T., Masubuchi Y., and Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J. Immunol. 160 (1998) 5493-5499
13. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., Foster C.A., Zollinger M., and Lynch K.R. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277 (2002) 21453-21457
14. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parsons W., and Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
15. Brinkmann V., and Lynch K. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr. Opin. Immunol. 14 (2002) 569-575
16. Pinschewer D.D., Ochsenbein A.F., Odermatt B., Brinkmann V., Hengartner H., and Zinkernagel R.M. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 164 (2000) 5761-5770
17. Chiba K., Yanagawa Y., Masubuchi Y., Kataoka H., Kawaguchi T., Ohtsuki M., and Hoshino Y. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160 (1998) 5037-5044
18. Shimizu H., Takahashi M., Kaneko T., Murakami T., Hakamata Y., Kudou S., Kishi T., Fukuchi K., Iwanami S., Kuriyama K., Yasue T., Enosawa S., Matsumoto K., Takeyoshi I., Morishita Y., and Kobayashi E. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 111 (2005) 222-229
19. Gett A.V., and Hodgkin P.D. A cellular calculus for signal integration by T cells. Nat. Immunol. 1 (2000) 239-244
20. Bouwens L., Remels L., Baekeland M., Van Bossuyt H., and Wisse E. Large granular lymphocytes or "pit cells" from rat liver: isolation, ultrastructural characterization and natural killer activity. Eur. J. Immunol. 17 (1987) 37-42
21. Kollet O., Shivtiel S., Chen Y.Q., Suriawinata J., Thung S.N., Dabeva M.D., Kahn J., Spiegel A., Dar A., Samira S., Goichberg P., Kalinkovich A., Arenzana-Seisdedos F., Nagler A., Hardan I., Revel M., Shafritz D.A., and Lapidot T. HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J. Clin. Invest. 112 (2003) 160-169
22. Hwang M.W., Matsumori A., Furukawa Y., Ono K., Okada M., Iwasaki A., Hara M., and Sasayama F. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation 100 (1999) 1322-1329
23. Brinkmann V., Pinschewer D.D., Feng L., and Chen S. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 72 (2001) 764-769
24. Brinkmann V., Chen S., Feng L., Pinschewer D., Nikolova Z., and Hof R. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant. Proc. 33 (2001) 530-531
25. Matsuura M., Imayoshi T., and Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int. J. Immunopharmacol. 22 (2000) 323-331
26. Kitabayashi H., Isobe M., Watanabe N., Suzuki J., Yazaki Y., and Sekiguchi M. FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. J. Cardiovasc. Pharmacol. 35 (2000) 410-416
27. Okazaki H., Hirata D., Kamimura T., Sato H., Iwamoto M., Yoshio T., Masuyama J., Fujimura A., Kobayashi E., Kano S., and Minota S. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J. Rheumatol. 29 (2002) 707-716
28. Hozumi Y., Kobayashi E., Miyata M., and Fujimura A. Immunotherapy for experimental rat autoimmune thyroiditis using a novel immunosuppressant, FTY720. Life Sci. 65 (1999) 1739-1745
29. Kimura T., Boehmler A.M., Seitz G., Kuci S., Wiesner T., Brinkmann V., Kanz L., and Mohle R. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells. Blood 103 (2004) 4478-4486